12/19
11:38 am
cogt
Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $65.00 to $67.00. They now have an "overweight" rating on the stock.
Low
Report
Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $65.00 to $67.00. They now have an "overweight" rating on the stock.
12/15
06:13 pm
cogt
Cogent Biosciences: Time For A Pause [Seeking Alpha]
Low
Report
Cogent Biosciences: Time For A Pause [Seeking Alpha]
12/8
12:13 pm
cogt
Cogent Biosciences (NASDAQ:COGT) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
Cogent Biosciences (NASDAQ:COGT) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
12/8
11:41 am
cogt
Cogent Biosciences (NASDAQ:COGT) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.
Low
Report
Cogent Biosciences (NASDAQ:COGT) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.
12/8
07:30 am
cogt
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Low
Report
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
12/6
09:30 am
cogt
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)
Medium
Report
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)
11/25
01:49 pm
cogt
Cogent Biosciences (NASDAQ:COGT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Cogent Biosciences (NASDAQ:COGT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/16
11:28 am
cogt
Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress [Yahoo! Finance]
Low
Report
Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress [Yahoo! Finance]
11/14
08:00 am
cogt
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
Low
Report
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
11/13
08:11 am
cogt
Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at HC Wainwright from $21.00 to $50.00. They now have a "buy" rating on the stock.
Medium
Report
Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at HC Wainwright from $21.00 to $50.00. They now have a "buy" rating on the stock.
11/13
01:17 am
cogt
Cogent Biosciences (COGT) Is Up 144.5% After Bezuclastinib Phase 3 Win and $500M Capital Raise Has The Bull Case Changed? [Yahoo! Finance]
Low
Report
Cogent Biosciences (COGT) Is Up 144.5% After Bezuclastinib Phase 3 Win and $500M Capital Raise Has The Bull Case Changed? [Yahoo! Finance]
11/11
11:16 pm
cogt
Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031
Medium
Report
Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031
11/11
01:11 pm
cogt
Cogent Biosciences (COGT) Climbs to New Record High on Cancer Treatment Drug Trial [Yahoo! Finance]
Low
Report
Cogent Biosciences (COGT) Climbs to New Record High on Cancer Treatment Drug Trial [Yahoo! Finance]
11/11
10:38 am
cogt
Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside [Seeking Alpha]
Medium
Report
Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside [Seeking Alpha]
11/11
08:16 am
cogt
Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at Robert W. Baird from $14.00 to $34.00. They now have a "neutral" rating on the stock.
Medium
Report
Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at Robert W. Baird from $14.00 to $34.00. They now have a "neutral" rating on the stock.
11/10
04:23 pm
cogt
Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at Leerink Partners from $18.00 to $50.00. They now have an "outperform" rating on the stock.
Medium
Report
Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at Leerink Partners from $18.00 to $50.00. They now have an "outperform" rating on the stock.
11/10
04:01 pm
cogt
Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock
Medium
Report
Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock
11/4
08:17 am
cogt
Cogent Biosciences (NASDAQ:COGT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Medium
Report
Cogent Biosciences (NASDAQ:COGT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
11/3
09:01 am
cogt
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results
Medium
Report
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results
11/3
09:00 am
cogt
Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting
Medium
Report
Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting
10/24
08:38 pm
cogt
Cogent Biosciences (COGT): Assessing Valuation After a 94% Year-to-Date Share Price Surge [Yahoo! Finance]
Medium
Report
Cogent Biosciences (COGT): Assessing Valuation After a 94% Year-to-Date Share Price Surge [Yahoo! Finance]
10/24
12:30 pm
cogt
Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Low
Report
Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/21
08:05 am
cogt
Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $30.00 to $44.00. They now have an "overweight" rating on the stock.
Medium
Report
Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $30.00 to $44.00. They now have an "overweight" rating on the stock.
10/20
08:32 am
cogt
Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib
Medium
Report
Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib
10/15
07:01 pm
cogt
Cogent Biosciences (NASDAQ:COGT) was given a new $16.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Cogent Biosciences (NASDAQ:COGT) was given a new $16.00 price target on by analysts at Stifel Nicolaus.